Q2 EPS Forecast for Denali Therapeutics Lifted by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at HC Wainwright increased their Q2 2025 EPS estimates for Denali Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.68) per share for the quarter, up from their previous forecast of ($0.69). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($2.39) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $2.15 EPS.

DNLI has been the topic of several other reports. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 target price on the stock. Morgan Stanley began coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They issued an “overweight” rating and a $33.00 price target on the stock. William Blair raised Denali Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. B. Riley reiterated a “buy” rating and issued a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Finally, Robert W. Baird lowered their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a research report on Thursday. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Buy” and an average price target of $33.79.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $14.39 on Monday. The firm’s 50 day simple moving average is $14.27 and its 200-day simple moving average is $19.99. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The company has a market cap of $2.09 billion, a P/E ratio of -5.21 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the firm earned ($0.68) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DNLI. Norges Bank bought a new stake in Denali Therapeutics in the 4th quarter valued at $21,717,000. Vanguard Group Inc. raised its stake in shares of Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after buying an additional 843,996 shares in the last quarter. Polar Asset Management Partners Inc. boosted its position in shares of Denali Therapeutics by 1,240.9% during the 4th quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company’s stock valued at $11,231,000 after acquiring an additional 509,992 shares in the last quarter. Balyasny Asset Management L.P. boosted its holdings in Denali Therapeutics by 822.4% during the fourth quarter. Balyasny Asset Management L.P. now owns 416,074 shares of the company’s stock valued at $8,480,000 after purchasing an additional 370,966 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Denali Therapeutics by 571.8% in the 4th quarter. Millennium Management LLC now owns 404,224 shares of the company’s stock valued at $8,238,000 after buying an additional 344,056 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.